Urolithin A Supplement

## What it is Urolithin A (UA) is a gut-microbiome-derived metabolite of ellagitannins, polyphenolic compounds concentrated in pomegranates, walnuts, raspberries, and certain other fruits. Ellagitannins themselves are not absorbed intact in the gut; they undergo hydrolysis to ellagic acid in the small intestine and are then converted by colonic bacteria into urolithins (A, B, C, D, and others). Urolithin A is the principal microbial metabolite of interest because it has the most-characterized biological activity. The critical observation that drives the supplement market is that gut microbiome composition determines whether an individual produces urolithin A from dietary ellagitannins. Roughly 40% of adults across studied populations have the microbial machinery to produce detectable urolithin A from pomegranate juice or walnut intake; the remaining ~60% are 'low producers' or 'non-producers' regardless of dietary intake. This producer/non-producer split makes direct supplementation attractive: it bypasses the variable microbial conversion step. The academic case for UA centers on mitophagy, the selective autophagic degradation of damaged mitochondria. Ryu 2016 (Nature Medicine, Amazentis collaboration) reported that UA improved mitochondrial function and extended lifespan in C. elegans by 45%, and improved muscle function and exercise capacity in aged rodents. The publication established UA as a mitophagy inducer with cross-species effects. The supplement product Mitopure was developed by Amazentis (Lausanne, Switzerland), which holds the patent on direct urolithin A supplementation and conducts most of the human clinical trial work. The product received Generally Recognized as Safe (GRAS) designation from the FDA in 2018 and Novel Food approval from EFSA in 2021. Most published human trials of UA have been Amazentis-funded or Amazentis-collaborated, which is the principal source of evidence-quality concern: the trials are well-designed but the funding monoculture means independent replication is thin. ## Mechanism of action Urolithin A's primary characterized action is induction of mitophagy. Mitochondria accumulate damage with cellular age, and mitophagy is the quality-control process that selectively degrades damaged mitochondria, allowing healthy ones to be replaced via mitochondrial biogenesis. The cumulative result of effective mitophagy plus biogenesis is mitochondrial network rejuvenation. The molecular mechanism involves PINK1/Parkin signaling, the central mitophagy pathway. Damaged mitochondria depolarize, stabilizing PINK1 on the outer membrane, which recruits the E3 ubiquitin ligase Parkin. Parkin ubiquitinates outer membrane proteins, marking the mitochondrion for selective autophagic degradation. UA appears to potentiate this signaling, increasing mitophagic flux without requiring the organelle damage that normally triggers it. The net effect in tissue is a mitochondrial network shifted toward healthier, younger-functioning organelles. UA also has antioxidant activity and anti-inflammatory effects independent of mitophagy. It modulates NF-kB signaling and reduces pro-inflammatory cytokine production in macrophages and other immune cells. The relative contribution of mitophagy versus these alternate mechanisms to clinical outcomes is not fully characterized. Pharmacokinetics in humans: oral UA is absorbed and reaches plasma levels in the low micromolar range at supplemental doses. Glucuronidation produces UA-glucuronide as the principal circulating form, with smaller amounts of free UA and UA-sulfate. Plasma half-life is roughly 17 hours, supporting once-daily dosing. Tissue uptake into muscle has been demonstrated. ## Evidence base by outcome ### Safety and PK in humans A-tier on safety. Andreux 2019 (Nature Metabolism) was the first-in-human trial: 60 healthy older adults randomized to placebo or UA at 250, 500, 1000, or 2000 mg daily for 4 weeks. Primary outcome was safety; secondary outcomes included plasma PK, muscle gene expression, and urolithin metabolites. Safety was favorable across doses. Muscle gene expression analysis showed dose-dependent upregulation of mitochondrial genes, with the strongest signal at 500 to 1000 mg. ### Muscle function and endurance B-tier (Amazentis-funded). Singh 2022 (JAMA Network Open) randomized 66 older adults (65 to 90) to placebo or UA 1000 mg daily for 4 months. Primary endpoint was 6-minute walk distance and muscle endurance. The UA arm showed improved muscle endurance (peak power and time to fatigue in hand and leg muscles), though the 6-minute walk did not differ significantly. Liu 2022 (Cell Reports Medicine) reported improvements in muscle mitochondrial respiration in older adults at the same dose. The pattern is consistent across the trial portfolio but the funding monoculture warrants caveats. ### Mitochondrial gene expression A-tier on the surrogate endpoint. Multiple trials report dose-dependent upregulation of mitochondrial respiration and biogenesis genes (PGC-1alpha, mitochondrial-encoded transcripts) in muscle biopsies after UA supplementation. The translation to functional outcomes is less robust. ### Inflammation and immune function C-tier. UA reduces pro-inflammatory cytokine production in mechanistic studies. Small clinical trials report modest reductions in inflammatory markers. Whether this translates to clinically meaningful immune-function improvement is unclear. ### Cognition C to D-tier. Preclinical studies report cognitive improvements in aged rodents. Human cognitive endpoints have not been a primary focus of UA trials; available data are exploratory. ### Cardiovascular function C-tier. Preclinical work suggests cardiac mitophagy benefits. A handful of small human studies report endothelial function improvements; the evidence base is preliminary. ### Skin aging C-tier. Topical and oral UA has been tested for skin aging endpoints with small trials reporting improvements in skin texture and structural markers. Evidence is preliminary. ### Longevity and healthspan D-tier on hard human endpoints. No completed RCT tests UA against frailty, healthspan, or all-cause mortality. The geroprotective hypothesis rests on preclinical data and short-term surrogate endpoints in humans. ## Dosage and administration The most-studied human dose is 500 to 1000 mg daily. Singh 2022 used 1000 mg/day; Andreux 2019 spanned 250 to 2000 mg with the 500 to 1000 mg range producing the strongest gene-expression signal without efficacy plateau. The 250 mg dose is sub-threshold on most surrogate endpoints. Doses above 1000 mg have not produced proportional benefit. Mitopure (Amazentis) is supplied as soft gels (typically 500 mg per gel) and powder. Generic synthetic UA products have proliferated since 2022; quality and bioavailability vary substantially across non-Amazentis products. Third-party-tested versions (NSF, USP) provide more reliable dosing. Morning dosing is conventional. Take with food (some fat content) to support absorption. The trials have used continuous daily dosing for 4 weeks (Andreux 2019) to 4 months (Singh 2022); longer-term data are limited. No cycling is part of the protocol. Whether continuous mitophagy stimulation produces tachyphylaxis or counter-regulatory adaptation has not been formally tested in long-duration human trials. Dietary alternatives: pomegranate juice (8 oz daily) and walnuts (1 oz daily) provide ellagitannin substrate. The roughly 40% of users who are urolithin producers may achieve modest UA exposure from food sources. Direct supplementation bypasses the producer-status uncertainty. ## Side effects and safety Safety has been favorable across the human trial portfolio. Adverse events in Andreux 2019 were similar between UA and placebo arms, with no dose-dependent toxicity signal. Singh 2022 reported no significant adverse events attributable to UA. Mild GI upset (nausea, soft stools) has been reported in a small minority across trials. No significant drug interactions are documented. UA is not metabolized by major CYP pathways and does not produce predictable pharmacokinetic interactions with prescription medications. Long-term safety beyond 4 months is not characterized. The compound has been on the market as Mitopure since 2020, with consumer-use observation periods now extending to several years without emergent safety signals. The food-source position (pomegranate, walnut metabolite) provides some reassurance about underlying compound safety. Pregnancy and lactation: data are insufficient. Routine use is not recommended. Potential interaction with chemotherapy: UA's mitochondrial effects could theoretically interact with chemotherapy agents that target mitochondrial function. Cancer patients should consult their oncologist before supplementation. ## Stack interactions and timing UA pairs reasonably with other mitochondrial-supporting compounds: CoQ10 (ubiquinol), NAD precursors (NMN, NR), creatine. The combinatorial evidence in humans is essentially absent; pairing is empirical. Resistance training and aerobic exercise both induce mitochondrial biogenesis through complementary pathways. Combining UA with structured exercise is mechanistically defensible and is the implicit context of the muscle-endurance trial portfolio. Spermidine and UA both target autophagy/mitophagy through different mechanisms. The combination has not been tested in humans. Dosing timing: morning with food is conventional. Taking with the first meal of the day supports absorption. ## Practical notes Mitopure (Amazentis) is the original branded product. Generic synthetic UA has proliferated since 2022 at substantially lower price points (10 to 30 USD per month versus 60 to 90 USD for Mitopure). Quality varies; bioavailability and content accuracy are the main concerns with non-branded products. Urolithin producer status testing is offered by some clinical labs (urinary urolithin metabolites after a pomegranate juice challenge). Knowing producer status changes the case for supplementation: non-producers cannot generate UA from food regardless of intake, so direct supplementation is the only option. Expect any benefit to accumulate over weeks to months. Surrogate gene-expression endpoints respond within 4 weeks; functional muscle endpoints in the Singh trial showed differences by 4 months. Anecdotal users describing dramatic short-term effects are likely experiencing placebo or coincident lifestyle changes. The honest framing for the use case: UA has plausible mechanism, favorable safety, and moderately encouraging short-term human surrogate-endpoint data. The trial portfolio is largely Amazentis-funded, which is a real evidence-quality concern despite well-designed individual trials. Long-term outcome data on healthspan or longevity do not exist. Anyone using UA for longevity is making an informed bet on indirect mechanism evidence and a strong preclinical case, not following a settled recommendation.